A medicine stock-out is defined by the World Health Organization (WHO) as “any time when, at a defined moment in a given ...

FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

A new State of Drug Access report shows that more than 40% of people living in the US could not afford their prescribed drugs ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO ...

Prescription drugs prices have rapidly increased, but opting for generic medications and incorporating lifestyle changes are some ways to cut costs.

Samsung Electronics is likely to spin off its foundry business from the broader semiconductor division, on the same conflict ...

Some Michigan hospitals are marking up prices by thousands of dollars above what they pay manufacturers for certain prescription drugs, according to a new report from the Michigan Health Purchasers ...

On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) ...